Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-04-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of funds raised by Beijing Northland Biotechnology Co., Ltd. It includes specifics about the amount raised, the use of funds, management of the funds, and compliance with regulatory requirements. It references approvals from the China Securities Regulatory Commission, details on the issuance of shares, and includes auditor and sponsor institution opinions verifying the proper use of the funds. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2021. This type of document is typically a specialized report on capital raising and fund usage, not a general annual report or earnings release. It is not a simple announcement but a substantive report with financial data and compliance details. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-04-25 Chinese
独立董事任命公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of an independent director at Beijing Northland Biotechnology Co., Ltd. It details the nomination, qualifications, and approval process for the new director. There is no financial data, earnings information, or report attached. The content focuses on board/management changes, specifically the appointment of a new independent director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear and specific content about management changes.
2022-04-25 Chinese
关于注销部分股票期权的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Beijing Northland Biotechnology Co., Ltd. regarding the cancellation of certain stock options under its first equity incentive plan. It details the background of the stock option plan, the reasons and quantities for the cancellation, and includes opinions from independent directors, the supervisory board, and legal counsel. The document is a formal disclosure about changes in the company's stock option plan, specifically the cancellation of stock options, which is a capital structure change. It is not a full financial report, audit, or management discussion, nor is it a voting result or a regulatory compliance filing. The content fits best under the category of Share Issue/Capital Change (SHA), as it concerns the cancellation (a capital change) of stock options granted to employees and executives. The document length is 3348 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is SHA with high confidence.
2022-04-25 Chinese
对外捐赠管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '对外捐赠管理制度' (External Donation Management System) issued by the company's board. It outlines principles, asset scope, types of donations, decision procedures, and other governance-related rules. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures approved by the board. The document length is 2711 characters, which is relatively short but contains substantive content about governance policies rather than a mere announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2022-04-25 Chinese
监事任命公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a new supervisor (监事) at Beijing Northland Biotech Co., Ltd. It details the nomination, qualifications, and impact of the appointment on the company's governance. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting presentation or voting results. The content clearly relates to changes in the company's board or senior management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management appointment, confirming this classification with high confidence.
2022-04-25 Chinese
2021年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告 AUDIT REPORT' and is issued by China Audit Asia Pacific Certified Public Accountants LLP. It specifically states it is the audit report for Beijing Northland Biotechnology Co., Ltd. for the fiscal year 2021. The content includes detailed audit opinions, basis for audit opinions, key audit matters, management responsibilities, and extensive financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed audit procedures, audit opinions, and financial data confirms this is a standalone audit report rather than a full annual report or other filing. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2021
2022-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.